Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | MECP2 | P51608 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278540 | 0.87 | NR1H2 (0.52) | NR1H2NR1H3ADORA2AADORA1ADORA2B | |
| SCHEMBL3279123 | 0.83 | MAOA (0.42) | NR1H2NR1H3MAOAAURKAMECP2 | |
| SCHEMBL3278690 | 0.83 | NR1H2 (0.53) | NR1H2NR1H3ADORA1MAPTDHODH | |
| SCHEMBL3279360 | 0.81 | NR1H2 (0.69) | NR1H2NR1H3 | |
| SCHEMBL1125016 | 0.80 | NR1H2 (0.58) | NR1H2NR1H3MAOAADORA2AADORA1 | |
| SCHEMBL3279134 | 0.77 | NR1H2 (0.44) | NR1H2NR1H3DHODH | |
| SCHEMBL5506808 | 0.77 | NR1H2 (0.45) | NR1H2NR1H3ADORA2AADORA1ADORA2B | |
| SCHEMBL3285054 | 0.76 | CNR1 (0.55) | NR1H2NR1H3MAPTMEN1LMNA | |
| SCHEMBL3278573 | 0.73 | DHODH (0.46) | NR1H2NR1H3ADORA2AADORA1KDM4E | |
| SCHEMBL3279218 | 0.73 | DHODH (0.43) | NR1H2NR1H3ADORA2AADORA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | claimed |
| CN-101166730-A | Cinnoline compounds and their use as liver X receptor modilators | WYETH CORP (US) | 2008-04-23 | — | — | CN | claimed |
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| CN-101166730-A | Cinnoline compounds and their use as liver X receptor modilators | WYETH CORP (US) | 2008-04-23 | — | — | CN | disclosed |
| EP-1853566-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODULATORS | Wyeth (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060252757-A1 | Cinnoline compounds | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2006094034-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS | WYETH (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252757-A1 | Cinnoline compounds | NR1H3, NR1H2, CNR1 | NR1H2 2/4885NR1H3 1/4885MAOA 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.